GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

기사 요약

GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.